Strategic targeting of the PI3K–NFκB axis in cisplatin-resistant NSCLC

References

• Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2:533 - 43; http://dx.doi.org/10.1016/S1470-2045(01)00486-7; PMID: 11905707
   PubMed Web of Science ®Google Scholar
• Pfannschmidt J, Muley T, Bülzebruck H, Hoffmann H, Dienemann H. Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients. Lung Cancer 2007; 55:371 - 7; http://dx.doi.org/10.1016/j.lungcan.2006.10.017; PMID: 17123661
   PubMed Web of Science ®Google Scholar
• Godwin P, Baird AM, Heavey S, Barr MP, O’Byrne KJ, Gately K. Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol 2013; 3:120; http://dx.doi.org/10.3389/fonc.2013.00120; PMID: 23720710
   PubMedGoogle Scholar
• Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A 1992; 89:3070 - 4; http://dx.doi.org/10.1073/pnas.89.7.3070; PMID: 1348364
   PubMed Web of Science ®Google Scholar
• Yang H, Kong W, He L, Zhao JJ, O’Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68:425 - 33; http://dx.doi.org/10.1158/0008-5472.CAN-07-2488; PMID: 18199536
   PubMed Web of Science ®Google Scholar
• Whitman M, Kaplan DR, Schaffhausen B, Cantley L, Roberts TM. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 1985; 315:239 - 42; http://dx.doi.org/10.1038/315239a0; PMID: 2987699
   PubMed Web of Science ®Google Scholar
• Currie RA, Walker KS, Gray A, Deak M, Casamayor A, Downes CP, Cohen P, Alessi DR, Lucocq J. Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem J 1999; 337:575 - 83; http://dx.doi.org/10.1042/0264-6021:3370575; PMID: 9895304
   PubMed Web of Science ®Google Scholar
• Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J 2008; 415:333 - 44; http://dx.doi.org/10.1042/BJ20081056; PMID: 18842113
   PubMed Web of Science ®Google Scholar
• Peng DJ, Wang J, Zhou JY, Wu GS. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Commun 2010; 394:600 - 5; http://dx.doi.org/10.1016/j.bbrc.2010.03.029; PMID: 20214883
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhang K, Liu Z, Hao F, Wang M, Li X, Yin Z, Liang H. Secreted clusterin gene silencing enhances chemosensitivity of a549 cells to cisplatin through AKT and ERK1/2 pathways in vitro. Cell Physiol Biochem 2014; 33:1162 - 75; http://dx.doi.org/10.1159/000358685; PMID: 24751980
   PubMed Web of Science ®Google Scholar
• Wang M, Liu ZM, Li XC, Yao YT, Yin ZX. Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells. J Chemother 2013; 25:162 - 9; http://dx.doi.org/10.1179/1973947812Y.0000000056; PMID: 23783141
   PubMed Web of Science ®Google Scholar
• Lee MW, Kim DS, Min NY, Kim HT. Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin. Int J Cancer 2008; 122:2380 - 4; http://dx.doi.org/10.1002/ijc.23371; PMID: 18224693
   PubMed Web of Science ®Google Scholar
• Belyanskaya LL, Hopkins-Donaldson S, Kurtz S, Simões-Wüst AP, Yousefi S, Simon HU, Stahel R, Zangemeister-Wittke U. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer 2005; 117:755 - 63; http://dx.doi.org/10.1002/ijc.21242; PMID: 15981204
   PubMed Web of Science ®Google Scholar
• Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28:1075 - 83; http://dx.doi.org/10.1200/JCO.2009.25.3641; PMID: 20085938
   PubMed Web of Science ®Google Scholar
• Heavey S, O'Byrne KJ, Gately K. Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treat Rev 2014; 40:445 - 56; http://dx.doi.org/10.1016/j.ctrv.2013.08.006; PMID: 24055012
   PubMed Web of Science ®Google Scholar
• Genentech. Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy. ClinicalTrialsgov [Internet]. Available from: http://clinicaltrials.gov/ct2/show/NCT01437566?term=GDC-0980&rank=6: Accessed 28/04/13, Identifier: NCT01437566; 2011.
   Google Scholar
• Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, Lesnick JD, Lewis C, Nonomiya J, Pang J, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 2011; 10:2426 - 36; http://dx.doi.org/10.1158/1535-7163.MCT-11-0446; PMID: 21998291
   PubMed Web of Science ®Google Scholar
• Jacobs MD, Harrison SC. Structure of an IkappaBalpha/NF-kappaB complex. Cell 1998; 95:749 - 58; http://dx.doi.org/10.1016/S0092-8674(00)81698-0; PMID: 9865693
   PubMed Web of Science ®Google Scholar
• Régnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M. Identification and characterization of an IkappaB kinase. Cell 1997; 90:373 - 83; http://dx.doi.org/10.1016/S0092-8674(00)80344-X; PMID: 9244310
   PubMed Web of Science ®Google Scholar
• Arenzana-Seisdedos F, Turpin P, Rodriguez M, Thomas D, Hay RT, Virelizier JL, Dargemont C. Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J Cell Sci 1997; 110:369 - 78; PMID: 9057089
   PubMed Web of Science ®Google Scholar
• Emmerich F, Meiser M, Hummel M, Demel G, Foss HD, Jundt F, Mathas S, Krappmann D, Scheidereit C, Stein H, et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 1999; 94:3129 - 34; PMID: 10556199
   PubMed Web of Science ®Google Scholar
• Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IkBa gene in Hodgkin’s disease suggest a tumour suppressor role for IkappaBalpha. Oncogene 1999; 18:3063 - 70; http://dx.doi.org/10.1038/sj.onc.1202893; PMID: 10340377
   PubMed Web of Science ®Google Scholar
• Ariga A, Namekawa J, Matsumoto N, Inoue J, Umezawa K. Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem 2002; 277:24625 - 30; http://dx.doi.org/10.1074/jbc.M112063200; PMID: 11983688
   PubMed Web of Science ®Google Scholar
• Kikuchi E, Horiguchi Y, Nakashima J, Kuroda K, Oya M, Ohigashi T, Takahashi N, Shima Y, Umezawa K, Murai M. Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice. Cancer Res 2003; 63:107 - 10; PMID: 12517785
   PubMed Web of Science ®Google Scholar
• Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, Umezawa K, Yamashita S. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin. Clin Cancer Res 2004; 10:6821 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-04-0463; PMID: 15501958
   PubMed Web of Science ®Google Scholar
• Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res 2005; 11:1287 - 93; PMID: 15709200
   PubMed Web of Science ®Google Scholar
• Watanabe M, Dewan MZ, Okamura T, Sasaki M, Itoh K, Higashihara M, Mizoguchi H, Honda M, Sata T, Watanabe T, et al. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int J Cancer 2005; 114:32 - 8; http://dx.doi.org/10.1002/ijc.20688; PMID: 15523684
   PubMed Web of Science ®Google Scholar
• Katsman A, Umezawa K, Bonavida B. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent. Drug Resist Updat 2007; 10:1 - 12; http://dx.doi.org/10.1016/j.drup.2007.01.002; PMID: 17306602
   PubMed Web of Science ®Google Scholar
• Katsman A, Umezawa K, Bonavida B. Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. Curr Pharm Des 2009; 15:792 - 808; http://dx.doi.org/10.2174/138161209787582156; PMID: 19275643
   PubMed Web of Science ®Google Scholar
• Castro-Gamero AM, Borges KS, da Silva Silveira V, Lira RC, de Paula Gomes Queiroz R, Valera FC, Scrideli CA, Umezawa K, Tone LG. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells. Anticancer Drugs 2012; 23:638 - 50; http://dx.doi.org/10.1097/CAD.0b013e328350e835; PMID: 22382389
   PubMed Web of Science ®Google Scholar
• Umezawa K. Possible role of peritoneal NF-κB in peripheral inflammation and cancer: lessons from the inhibitor DHMEQ. Biomed Pharmacother 2011; 65:252 - 9; http://dx.doi.org/10.1016/j.biopha.2011.02.003; PMID: 21723080
   PubMed Web of Science ®Google Scholar
• Lake A, Shield LA, Cordano P, Chui DT, Osborne J, Crae S, Wilson KS, Tosi S, Knight SJ, Gesk S, et al. Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases. Int J Cancer 2009; 125:1334 - 42; http://dx.doi.org/10.1002/ijc.24502; PMID: 19507254
   PubMed Web of Science ®Google Scholar
• Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O’Flaherty JD, Fennell DA, Richard D, O’Leary JJ, O’Byrne KJ. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One 2013; 8:e54193; http://dx.doi.org/10.1371/journal.pone.0054193; PMID: 23349823
   PubMed Web of Science ®Google Scholar